There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Leerink Global Healthcare Conference 2025 March 10, 2025 11:20 AM ETCompany ParticipantsAlisha Alaimo - President of ...

Hemophilia A is a disorder that leads to nosebleeds, gastrointestinal bleeding, bruising, and more. The symptoms, which can be serious enough to require emergency care, occur due to a deficiency in ...

Biogen Option Activity Analysis: Last 30 Days Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and ...

Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. The New York pharma is ending global development and commercialization of ...

Real Chemistry, a leader in AI-driven insights and marketing communications for the healthcare sector, today announced the appointment of Jeff Lupinacci as Chief Financial Officer and Julia Gaebler, ...

What is Altuviiio for hemophilia? Altuviiio (efanesoctocog alfa) is an approved long-lasting factor VIII (FVIII) replacement therapy used to reduce the frequency of bleeding episodes or control and ...

Zorevunersen is intended for treating Dravet syndrome. Credit: Maks_lab/Shutterstock. Biogen has entered a collaboration with Stoke Therapeutics to develop and and commercialise zorevunersen to treat ...

CAMBRIDGE, Mass. & BEDFORD, Mass.--(BUSINESS WIRE)--Biogen Inc. (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK) today announced a collaboration for the ...

Through a new deal, Biogen has bought access to a potentially first-of-its-kind drug that some doctors and analysts see as a promising treatment for a rare form of epilepsy. Biogen on Tuesday ...